• Citer

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): Survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

par de Azambuja, Evandro ;Abdel Azim, Hatem Hamdy ;Holmes, Andrew A.P.;Holmes, Eileen;Piccart-Gebhart, Martine ;Di Cosimo, Serena;Swaby, Ramona R.F.;Untch, Michael;Jackisch, Christian;Lang, Istvan;Smith, Ian;Boyle, Frances;Xu, Binghe;Barrios, Carlos;Perez, Edith A;Kim, Sung-Bae;Kuemmel, Sherko;Huang, Chiun Sheng;Vuylsteke, Peter;Hsieh, Ruey Kuen;Gorbunova, Vera;Eniu, Alexandru;Dreosti, Lydia;Tavartkiladze, Natalia;Gelber, Richard;Eidtmann, Holger;Baselga, José
Référence Lancet oncology, 15, 10, page (1137-1146)
Publication Publié, 2014

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): Survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
Auteur:	de Azambuja, Evandro; Abdel Azim, Hatem Hamdy; Holmes, Andrew A.P.; Holmes, Eileen; Piccart-Gebhart, Martine; Di Cosimo, Serena; Swaby, Ramona R.F.; Untch, Michael; Jackisch, Christian; Lang, Istvan; Smith, Ian; Boyle, Frances; Xu, Binghe; Barrios, Carlos; Perez, Edith A; Kim, Sung-Bae; Kuemmel, Sherko; Huang, Chiun Sheng; Vuylsteke, Peter; Hsieh, Ruey Kuen; Gorbunova, Vera; Eniu, Alexandru; Dreosti, Lydia; Tavartkiladze, Natalia; Gelber, Richard; Eidtmann, Holger; Baselga, José
Informations sur la publication:	Lancet oncology, 15, 10, page (1137-1146)
Statut de publication:	Publié, 2014
Sujet CREF:	Cancérologie
MeSH keywords:	Administration, Oral
	Adult
	Aged
	Antibodies, Monoclonal, Humanized -- adverse effects -- therapeutic use
	Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
	Breast Neoplasms -- drug therapy -- metabolism -- mortality -- pathology
	Chemotherapy, Adjuvant
	Confidence Intervals
	Disease-Free Survival
	Dose-Response Relationship, Drug
	Drug Administration Schedule
	Female
	Follow-Up Studies
	Humans
	Infusions, Intravenous
	Maximum Tolerated Dose
	Middle Aged
	Neoadjuvant Therapy
	Neoplasm Invasiveness -- pathology
	Neoplasm Staging
	Quinazolines -- adverse effects -- therapeutic use
	Receptor, ErbB-2 -- metabolism
	Survival Analysis
	Treatment Outcome
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:1470-2045
	info:doi/10.1016/S1470-2045(14)70320-1
	info:pii/S1470204514703201
	info:scp/84908602324
	info:pmid/25130998